Yes, I was disappointed by the results of the Marianne trial between the T-DM1 arm and T-DM1+Perjeta arm, which came in with a median PFS of 14.1 vs 15.2, and a median DOR of 20.7 vs 21.2 months. The difference in these figures failed to show the SIGNIFICANT synergy between these compounds that was reported by I-SPY2 investigators in preclinic work with both agents. I wonder if administering of the drugs at Marianne sites somehow did impact these numbers.
http://cancerres.aacrjournals.org/co...S6-07.abstract
http://meetinglibrary.asco.org/content/147990-156
Hybrid Mode
